Favorable long-term survival using consolidation chemotherapy without allogeneic hematopoietic cell transplantation for acute myeloid leukemia with wild-type NPM1 without FLT3-ITD.

Content Provider	Europe PMC
Author	Baek, Dong Won Lee, Jung Min Kim, Ju-Hyung Cho, Hee Jeong Ham, Ji-Yeon Suh, Jang-Soo Sohn, Sang-Kyun Moon, Joon Ho
Copyright Year	2019
Abstract	Background The role of allogeneic hematopoietic cell transplantation (allo-HCT) compared with consolidation chemotherapy alone in intermediate-risk acute myeloid leukemia (AML) patients with wild-type nucleophosmin/negative or a low level of Fms related tyrosine kinase 3 internal tandem duplication (NPM1wt/FLT3-ITDneg/low) has not yet been elucidated. Methods In this study, we retrospectively investigated 88 patients newly diagnosed with AML who received intensive induction chemotherapy at Kyungpook National University Hospital from March 2015 to July 2017. The selection criteria included the presence of results on genetic abnormalities including NPM1 and FLT3-ITD. Results According to the European LeukemiaNet (ELN) risk classification, 25 patients (28%) were categorized as favorable, 44 (50%) as intermediate, and 19 (22%) as adverse risk. Among the intermediate-risk patients, 40 were identified as NPM1wt/FLT3-ITDneg/low. Among the patients with NPM1wt/FLT3-ITDneg/low, complete remission (CR) was achieved in 26 patients out of 40 (65%). One-year overall survival (OS) rate was 100% in the favorable-risk group and 87.9% in the NPM1wt/FLT3-ITDneg/low group (P=0.233). Among the intermediate-risk NPM1wt/FLT3-ITDneg/low patients, there was no survival benefit with allo-HCT (N=19) compared to consolidation chemotherapy (N=21; P=0.372). In the multivariate analysis, the ELN risk group [hazard ratio (HR), 6.36; P=0.019] and the achievement of CR (HR, 2.95; P=0.017) were both identified as factors affecting OS of patients with newly diagnosed AML. Conclusion Among the AML patients, intermediate-risk NPM1wt/FLT3-ITDneg/low patients and favorable-risk patients showed similar OS rates. Our results suggested that allo-HCT might have limited clinical benefit for the intermediate-risk NPM1wt/FLT3-ITDneg/low patients. Well controlled studies are needed to confirm the current results.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC6779939&blobtype=pdf
ISSN	2287979X
Volume Number	54
DOI	10.5045/br.2019.54.3.189
PubMed Central reference number	PMC6779939
Issue Number	3
PubMed reference number	31730679
Journal	Blood research [Blood Res]
e-ISSN	22880011
Language	English
Publisher	Korean Society of Hematology
Publisher Date	2019-09-25
Access Restriction	Open
Rights License	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2019 Korean Society of Hematology
Subject Keyword	Acute myeloid leukemia Allogeneic hematopoietic cell transplantation NPM1 FLT3-ITD
Content Type	Text
Resource Type	Article
Subject	Hematology